

专科制药模式是创新的主要驱动力三只评为买入，一只评为卖出
我们认为中国医药行业正在经历涉及研发风险回报、处方结构、市场准入等各个方面的重大转型，其背后的推动力量是始于2015年末且在2016/17年进一步深化的药品审评审批制度改革。我们认为研发对国内企业至为关键，并认为特色专科药模式是从普通仿制药过渡到创新药的一条可行的转型路径。我们认为临床开发能力是释放研发价值的关键所在。
我们认为未来的领军企业包括：1)为创新提供服务的合同研究组织(CRO)；2)侧重治疗率不足的大病（如肿瘤、糖尿病、中枢神经系统疾病）或新兴细分领域（如老年性黄斑病变、生育、免疫抑制等），并拥有创新生物和小分子产品（创新药或优质仿制药）的特色专科药企。我们首次覆盖10家A/H股药企和CRO公司。
我们采用高盛专有行业评分卡评估这些企业的行业定位、增长、创新和进入壁垒，其中：
泰格医药（买入，12个月目标价格人民币39.80元，上涨空间24%）：领先的临床CRO公司，国内医药创新趋势的战略性受益者，推动因素包括临床试验供应限制的缓解、强劲的后备订单和潜在的并购。通化东宝（买入，12个月目标价格人民币27.72，上涨空间25%）：国内领先的胰岛素企业，其患者群体持续增长，县级市场的渗透率提升，即将推出的胰岛素类似物将带动产品升级。华东医药（买入，12个月目标价格人民币66.28元，上涨空间24%）：国内领先的口服糖尿病药（阿卡波糖）供应商，其独特的免疫抑制剂产品正逐渐发力。华海药业（卖出，12个月目标价格人民币20.88元，下跌空间18%）：从特色原料药转型为仿制药企业，但美国仿制药受到的产品降价、监管趋严以及建立销售队伍所需投入为主要风险。
注：股价截至2017年10月30日收盘。

全文翻译将随后提供。
北京高华证券有限责任公司及其关联机构与其研究报告所分析的企业存在业务关系，并且继续寻求发展这些关系。因此，投资者应当考虑到本公司可能存在可能影响本报告客观性的利益冲突，不应视本报告为作出投资决策的唯一因素。有关分析师的申明和其他重要信息，见信息披露附录，或请与您的投资代表联系。
































'17-'19eReimbursement2016salesCAGREDLRDLBrandnameMolecule/genericnameDosageformIndicationRmbmn%%(GSe)NP2017N2009NProvincialTigermed(300347.SZ)-ClinicalCROleaderpoisedforstrongergrowthwithimprovingexecutionamidpositiveregulationchangesClinicaltrialtechnicalservices47440%36%ClinicaltrialservicesCoversphaseI-IVtrials,providingone-stopsolutions42936%38%BioequivalencestudyProvideservicesforgenericscompaniesforinvitro/invivobioequivalentstudies454%25%Clinicaltrialrelatedconsultingservices68859%20%Coversavarietyofservicesmainlyincludingclinicaltrialstatistics,datamanagement,sitemanagementorganization(SMO),medicalimagingetcTonghuaDongbao(600867.SS)-LeadingdomestichumaninsulinsupplierwithupcominginsulinanalogproductGansulin30Rrhinsulin,30/70premixInjectionsDiabetes1,199GansulinRrhinsulinInjectionsDiabetes144Gansulin50Rrhinsulin,50/50premixInjectionsDiabetes122Gansulin40Rrhinsulin,40/60premixInjectionsDiabetes61GansulinNrhinsulinNPHInjectionsDiabetes43InsulinAPI-API-29Insulinpens,bloodglucosemeter&teststripsDevicesDiabetes233ZhennaoningcapsulesCapsulesCerebrovasculardiseases67Huahai(600521.SS)-SpecialtyAPIsuppliertransitionedbusinessfocustoUSANDAanddomesticgenericsDomesticfinisheddrugs770-404-119ExportedANDA768-Lamotrigine139-Valsartan163-Ropinirole109SpecialtyAPI(Cardiovascular&CNSfocused)1,882-ARBs(-sartan)APICardiovascularAPIs887-ACEIs(-pril)APICardiovascularAPIs366-Anti-EpilepticsAPICNSAPIs324-Anti-AIDSAPIAnti-viralAPIs76HuadongMedicine(000963.SZ)-Topregionaldistributorandleadingplayerinoralanti-diabeticgenericsFlagshipproductsBailingcapsules(百令胶囊)FermentedcordycepsKaboping(卡博平)AcarboseImmunosuppressorportfolioXinSaiSiPing(新赛斯平)CyclosporineSaiKePing(赛可平)MycophenolatemofetilSaiFuKai(赛福开)TacrolimusDigestivesystemPanLiSu(泮立苏)PantoprazoleInjectionsGIulcer71113%*:HuadongalsoownsZhejiang'stop3distributornetwork,distributionaccountedfor78%ofrevenueand23%ofgrossprofitin'16


'17-'19eReimbursement2016salesCAGREDLBrandnameMolecule/genericnameDosageformIndicationRmbmn%%(GSe)NPLivzon(000513.SZ/1513.HK)-Specialtypharmawithleadingfertility/GIportfolioandmicrospheresplatform,tappingintobiologicsR&DGonadotropichormones1,18015%21%Lishenbao(丽申宝)5447%15%Beiyi(贝依)3865%32%
Gastrointestinal7189%30%Yili'an(壹丽安)2854%31%LizhuDele(丽珠得乐)1192%9%Antibiotics3855%5%Lifukang(丽福康)1252%5%Kanglineng(康丽能)1031%0%Otherwesterndrugs90312%10%Likangle(丽康乐)4916%15%TCM2,12628%4%ShenqiFuzhenginjections(参芪扶正注射液)Injections1,68022%3%Anti-viralgranulesGranules2443%11%Bulkmedicine(e.g.acarbose,mycophenolicacid,etc.)1,73623%10%Diagnositics5687%11%BettaPharma(300558.SZ)-Innovativestart-upwithinitialcommercialsucessson1stdomesticlungcancertargetedtherapy(Icotinib)Commana(凯美纳)IcotinibTabletsEGFR+NSCLC1,035100%26%XXKanghong(002773.SZ)-EmergingleaderinwetAMDtreatmentwithnovelbiologictherapy(Conbercept)LangMu(朗沐)ConberceptInjectionswetAMDChemicaldrugsXinLuoNa(新络纳)BoSiQing(博思清)BoLeXin(博乐欣)TCMSonglingXuemaikangCapsules(松龄血脉康胶囊)YiQingCapsules(一清胶囊)DanShuCapsules(胆舒胶囊)ShuganJieyuCapsules(舒肝解郁胶囊)


Kelun(002422.SZ)-No.1infusionsolutionplayerbuildingR&Dcapability/pipeline;antibioticsAPIbusinesstorecoverfromtroughInfusionsolutionsInjections6,00970%Formulations1,12213%BaiLuoTe(百洛特)~100~1%APIproduct1,10213%ErythromycinthiocyanateCapacityof3,000tonsAPI-6958%7-ACACapacityof5,000tonsAPI-2283%PenicillinGCapacityof3,000tonsAPI-390%6-APACapacityof4,000tonsAPI-1402%*:Reimbursement:EDL&RDL(A),100%covered;RDL(B),reimbursementratesvaryfromprovincetoprovince,60-90%;RDL(R),reimbursedwithrestrictions
UnitedLabs(3933.HK)-MajorantibioticsAPImanufacturerswithemerginginsulinbusinessFinishedproductUSLIN(优思灵)RecombinantinsulinInjections(pen/cartridge)DiabetesUSLEN(优乐灵)InsulinglargineInjections(pen/cartridge)DiabetesAntibioticsportfolio(penicillins,cephalosporins,β-lactamaseinhibitor&carbapenems)AntibioticsAPIproductIntermediate(6-APA,penicillinGpotassiumfirstcrystal)Bulkmedicine(penicillinstypes,cephalosporinstype,β-lactamaseinhibitortype)













Founded:2004|Headquarter:Hangzhou,Zhejiang-Chairman:Mr.YeXiaoping(叶小平)-A-shareIPO:August2012|Marketcap:Rmb15.8bn(~US$2.4bn),asofOctober27,2017-Corebusinesssegments:Clinicaltrialtechnicalservices(40.3%ofthesalesin'16),Clinicaltrialrelatedconsultingservices(58.6%),andotherservices(1.1%)KeyHighlightsNotes2H17/2018/2019Outlook

























Founded:1985|Headquarter:Tonghua,JilinProvince-Chairman:Mr.LiYikui(李一奎)-A-shareIPO:August1994|Marketcap:Rmb37.8bn(~US$5.7bn),asofOctober27,2017-Corebusinesssegments:Insulinportfolioproducts(78.4%ofthesalesin'16)anddiabetesdevices(11.4%)KeyHighlightsNotes


Synergieswithinsulinmarketing/sales.BecamesoledistributorofBionime(华广生技)'sproductsin2016,particularlyglucoseteststrips"RuiTe瑞特"(overRmb100m,doubledin2016).














Prandilin25R速秀霖25(25%Insulinlispro)Insulinaspart30NDAfiled,50INDfiled













Founded:1993|Headquarter:Hangzhou,Zhejiangprovince-Chairman:Mr.LiBangliang(李邦良)-A-shareIPO:1999,December|Marketcap:Rmb53.1bn(~US$8.0bn),asofOctober27,2017-Businesssegments:pharmamanufacturingandpharmadistributionKeyHighlightsNotes
Flagshipproducts:-Fermentedcordyceptspowdercapsules(brand:Corbrincapsule百令胶囊):'16salesofc.Rmb2bn(+22%y/y).CorbrincapsuleisanexclusiveTCMproductforsupportivetreatmentofkidney/lung-relatedchronicdiseases.Weexpecttheproducttogrowat+14.0%CAGRduring'17E-'19E,with:1)easingcapacityconstraintswiththecompletionofnewmanufacturingfacility(annualproductionof1,200tonsoffermentedcordycepspowder)inJuly'16;2)furtherpenetrationintoOTCchannels(theproductisapprovedforsalesinbothRx/OTCchannels)andgrassrootsmarkets,asthesetwomarketsonlyaccountedfor~10%ofproductsales.However,giventhattheproductisnotusedasacoretherapyandhasreachedarelativelylargesalesbase,weseepotentialgrowthheadwindsfromtheongoingcostcontrolpolicyinhospitals(theproductwaslistedondrugusemonitorlistinJiangsuinOct'15).

Acarbosetablet(brand:Kaboping卡博平):'16salesofc.Rmb1.4bn(+25%y/y).ThegenericversionofBayer'sGlucobayforthefirst-linetreatmentoftype2diabetes.Sincelaunchingin2002,KabopinghasbeenconsistentlygainingmarketsharefromBayer,withmarketsharereaching~33%in'16basedonsamplehospitaldata(vs.Bayer's63%andLuye's4%).Weexpecttheproducttogrowat+18.3%CAGRduring'17E-'19E,withfurtherimportsubstitutiondrivenby:1)newreimbursementmodelfeaturingreimbursementreferencepricingtofavorlower-costgenerics(Kabopingpricedat~30%discounttoGlucobay);and2)Bayer'swithdrawaloftendersforGlucobayinGuangdong,ShandongandShaanxitoavertpriceerosion,leavingmoremarketstobetakenupbyHuadong/Luye.Moreso,weseethebetterreimbursementforacarboseinthenewNRDL(upgradedfromcatalogBtoA,implyingfullreimbursement)coulddrivethegrowth.


immunosuppressantportfolio:-Cyclosporine(brand:XinSaiSiPing新赛斯平):'16salesofc.Rmb437mn(+15%y/y).ThegenericversionofNovartis'sSandimmuneasimmunosuppressantfororgantransplant(liver/kidney/heart/marrow).Theproductcaptured49%ofmarketsharein'16basedonsamplehospitaldata,surpassingSandimmune(30%marketshare)asthebest-sellingbrandinChina.Weforecasttheproducttogrowat+7.5%CAGRduring'17E-'19E,highervs.low-singledigitgrowthforthecyclosporinemarketaswecontinuetoseeincrementalmarketsharegainfromSandimmune.

MycophenolateMofetilCapsules,MMF(brand:SaiKePing赛可平):'16salesofc.Rmb227mn(+31%y/y).ThegenericversionofRoche'sCellCeptasimmunosuppressantfororgantransplant(kidney/heart).Theproductcaptured30%ofmarketsharein'16basedonsamplehospitaldata,onlybehindCellCept(64%).MMFismainlyusedtoreplaceazathioprineascombinationaltherapywithcyclosporineortacrolimusinorgantransplantduetoitsbetterefficacyandsafetyprofile.Weforecasttheproducttogrowat+22.5%CAGRduring'17E-'19E,aswestillseeplentyofroomformarketsharegainfromCellCept.
Tacrolimus(brand:SaiFuKai赛福开):'16salesofc.Rmb237mn(+23%y/y).ThegenericversionofAstellas'sPrografindicatedforimmunosuppressionfororgantransplant(liver/kidney/heart/marrow).Theproductcaptured19%ofmarketsharein'16basedonsamplehospitaldata,onlybehindPrograf(62%).Tacrolimusisanewgenerationimmunosuppressantwithstrongerimmunosuppressivepotencybutcosts2-3timesmorevs.cyclosporine.Weforecasttheproducttogrowat+17.5%CAGRduring'17E-'19E,drivenbymarketsharegainfromPrografandreplacementofcyclosporinewithtacrolimusinhigher-tiermarkets.



























Founded:1989|Headquarter:Linhai,Zhejiangprovince-Chairman:Mr.TongJianxin(童建新)-A-shareIPO:2003,February|Marketcap:Rmb265bn(~US$4.0bn),asofOctober27,2017-Businesssegments:ManufacturerofAPIandgenericsfordomesticmarketandexportKeyHighlightsNotes





























Founded:1985|Headquarter:Zhuhai,Guangdongprovince-Chairman:Mr.ZhuBaoguo(朱保国),whoisalsotheChairmanofJoincare,theparentcompanyofLivzon-A-share/B-shareIPO:1993;HKIPO:2014,Jan|Marketcap:Rmb35bn(~US$5.3bn),asofOctober27,2017-Corebusinesssegments:Chemicaldrugs(42%ofsalesin'16),TCM(28%),APIs(23%),diagnostics(7.5%)KeyHighlightsNotes
Gonadotropichormonesproducts:-Leuprorelinacetatemicrospheres(brand:BeiYi贝依):'16salesofRmb386mn,+31%y/y(+46%+in1H17).AgenericcheaperversionofTakeda'sEnantone(passedbioequivalentstudy),the1stdomesticmicrosphereproductmarketedinChina.ApprovedbyCFDAin2009forfiveindications:endometriosis(contributed~40%ofsales),uterinefibroid(~20%),premenopausalbreastcancer,prostatecancerandcentralprecociouspuberty(restofthethreeindications,~10-15%ofsaleseach).
Twokeyhighpotentialproducts:-Ilaprazole(brand:YiLiAn壹丽安):licensedinfromKorean-basedIL-YangPharmin2001andregisteredinChinaasnovelnew-gengastriculcertherapyin2008.Belongstothecategoryofprotonpumpinhibitors(PPIs),betterefficacyandlowerdosevs.otherPPIs.'16salesofRmb285mnandmaintainedstronggrowthmomentumin1H17(+47%y/y).Keydriversin'17:1)NRDLinclusion;2)potentiallaunchofnewinjectionformulationinlate'17.

Mousenervegrowthfactor(mNGF,brand:LiKangLe丽康乐):'16salesofRmb491m(+63.8%y/y),slowerin1H(+19%y/y)duetowithdrawalfromGuangdongtendertodefendtheprices.Approvedforopticnervedamagein'11,competingwithmarketleaderStadison(salesofRmb1.2bnin'16,approvedin'05).


Coreproduct:ShenqiFuzhenginjection(参芪扶正):-Supportivemedicineincancertreatment.SalesofRmb1.68bnin'16.Thegrowthhasslowedinrecentyearsand+1.5%in1H17giventhecontrolofsupportivemedicinesinChinaandgrowingconcernsonTCMinjections'safetyprofiles.Managementtargetssingle-digitgrowthinthecomingyears,drivenbypenetrationintomid-tierhospitals.


Corescientists:Dr.XuPeng(徐朋),establishedfirstmicrosphereplatforminChinain2002,developedtheonlytwomicrosphereproductsmarketedinChina.Dr.RenBing(任兵),hasexperiencefromworkinginPfizer,AlkermesandJnJforglobalregistrationformicrospheres.
Pipelinehighlights:1)triptorelinmicrospheres(1-month):IND;2)leuprorelinmicrospheres(3-month):targetsYE17forIND;3)moreprojects:octreotide,triptorelin(3month),aripiprazole,risperidonemicrospheresCapacity:2000L(500L+1500Lstainlesssteellines)tobeputintooperation,capacitywillbefurtherexpanded.NewinvestmentofRmb600min2016(fundedbyprivateplacement).BiologicsR&Dteam:ledbyDr.FuDaotian(傅道田),LivzonhasbuiltabiologicsR&Dteamof~200staff,andcorescientistshave10+yearexperienceinmAbdevelopment










25.9%31.0%Yili'an(壹丽安)LizhuDele(丽珠得乐)Gastric/duodenalulcerGastritis



Lishenbao√LebaodeHCG(绒促性素)5%√HCGCetrorelix(西曲瑞克)6%xClomiphene(氯米芬)0.3%x*:includinguFSH,rhFSHandFSHbeta




Livzon(丽珠)2010200620032003Rmb491mnRmb1,239mnRmb800mnRmb766mn83.1%15.4%27.2%29.5%14.9%37.6%24.3%23.2%Rmb245Rmb217Rmb176Rmb176YYYY30μg(1,5000AU)30μg(1,5000AU)18μg(9,000AU)20μg(9,000AU)24months24months30months30monthsOpticalnerveOpticalnerveN-hexaneN-hexanedamagedamageinducedinducedperipheralperipheralneuropathneuropath







Founded:2003|Headquarter:Hangzhou,Zhejiangprovince-Chairman:Dr.DingLieming(丁列明)-A-shareIPO:November2016|Marketcap:Rmb28.2bn(~US$4.2bn),asofOctober27,2017-Coreproduct:Commana(Icotinib),theonlymarketeddrugfromthecompanyKeyHighlightsNotes








DrugManufacturerGlobalfirstapprovalChinaapprovalConmana(凯美纳,Icotinib)BettaPharma-2011,JuneIressa(易瑞沙,Gefitinib)Tarceva(特罗凯,Erlotinib)AstraZenecaRoche2002,JulyinJapan(2003intheU.S.)2004,Nov.inUSlate20042006,April
Yiruike(伊瑞可,Gefitinib)QiluPharma-2016,Oct(early2017launch)











Founded:1994|Headquarter:Chengdu,Sichuanprovince-Chairman:Mr.KeZunhong(柯尊洪),52.64%shares(25.68%directholding+26.96%indirectholdingthroughKanghongTechnology)-A-shareIPO:2015,June|Marketcap:Rmb427bn(~US$6.4bn),asofOctober27,2017-Businesssegments:chemicaldrugs,TCMandbiologic(Conbercept)KeyHighlightsNotes
CNSproducts:-AripiprazoleODtablets(brand:BoSiQing博思清):'16salesofRmb338m(+10%y/y).ThegenericversionofOtsuka'sAbilifyindicatedforthetreatmentofschizophreniaandbipolardisorder.Withanexclusiveformulation,theproductcaptured~37%marketshare(#2,basedonsamplehospitaldata),onlybehindAbilify.Withstabilizingmarketshareamongthethreemajorplayers,weexpecttheproducttogrowat10%CAGRduring'17E-'19E,in-linewiththegrowthofChinesearipiprazolemarket.

VenlafaxineHClSRtablets(brand:BoLeXin博乐欣):'16salesofRmb246m(+20.7%y/y).ThegenericversionofPfizer'sEffexorindicatedfordepression.Withanexclusiveformulation,theproductcaptured~37%marketshare(#2,basedonsamplehospitaldata),onlybehindEffexor.WithacleartrendofconsistentmarketsharegainfromEffexoroverthepastfiveyearsandlimitedpressurefromdomesticcompetitors(theremainingfivedomesticcompetitorsinthemarketonlyaccountfor<1%marketshare),weexpecttheproducttogrowat15.5%CAGRduring'17E-'19E.
Digestivesystemproducts:-Mosapridecitratedispensingtablets(brand:XinLuoNa新络纳):'16salesofRmb360mn(+18.8%y/y).Thethirdgenerationgastroprokineticagentforgastritisanddyspepsiawithimprovedsafetyprofileandtoleranceoverthefirst/secondgeneration's.Withanexclusiveformulation,theproductcaptured~48%marketshare(#1,basedonsamplehospitaldata)andweexpectthegrowthtobe9%CAGRduring'17E-'19Edrivenbymarketsharegainfromtheoriginator(Dainippon,#2),whilecompetitionfromdomesticplayers(4majorplayers)maylimitthepotentialofhighergrowth.



MajorityoftheTCMproductsarerelativelymatureandthecompetitionisintenseinthetherapeuticareasforwhichthekeydrugsareindicated:1)SonglingXuemaikangcapsules(松龄血脉康胶囊),launchedin1995andindicatedforhypertension/headache;2)YiQingcapsules(一清胶囊),launchedin1999andindicatedfordetoxication;3)DanShucapsules(胆舒胶囊),launchedin1990andindicatedforcholecystitis.

ShuganJieyucapsules(舒肝解郁胶囊),ontheotherhand,asarelativelynewproductlaunchedin2009andoneofthefewTCMsfortreatingdepression,couldbethekeygrowthdriver(GSestimates+19%CAGRover'17E-'19E)fortheTCMfranchisebenefitingfromKanghong'sestablishedchannelsinanti-depressionproducts.
Conbercept(brand:LangMu朗沐)-Class1innovativebiologicproductthattook~10yearstobringitfromdevelopmenttocommercialization-Asananti-VEGFrecombinantproteinindicatedforwAMD,LangMu'ssalesgrowthwillbedrivenby:1)marketsharegainfromLucentis(ranibizumab),theonlycompetitorofLangMuintheChineseanti-VEGFdrugsforwAMDtreatment,givenLangMu'sadvantageofshorterinjectionfrequency(50%lessinjectionsannually),whichimpliedbetteraffordability(50%lowerinannualcosts)andpatientexperiencevs.Lucentis;2)improvingpenetrationofanti-VEGFtherapy(first-linetreatment)inwAMDpatientwiththeinclusionofbothLangMuandLucentisintotheNRDLthroughnationalpricenegotiationinJuly'17.'-Themanufacturingcapacity(one1,200Landtwo750Lbioreactors)issufficienttofulfilldomesticdemand























Founded:1990|Headquarter:HongKong-Chairman:HoiShanTsoi(蔡海山)-H-shareIPO:June2007|Marketcap:HK$11.3bn(~US$1.4bn),asofOctober27,2017-Corebusinesssegments:antibioticsAPIs(intermediateproducts,20.3%ofthesalesin'16andbulkmedicines40.7%,andfinishedproducts(39%,mainlyantibioticsandinsulinportfolio)KeyHighlights











































Founded:1996|Headquarter:Chengdu,Sichuanprovince-Chairman:Mr.LiuGexin(刘革新),26.33%ofshares-A-shareIPO:2010,June|Marketcap:Rmb31.4bn(~US$4.7bn),asofOctober27,2017-Businesssegments:infusionsolutions;antibioticsAPIs;newdrugR&DKeyHighlightsNotes


TwomajorproductswithannualsalesofRmb100m+are:-Escitalopram(brand:BaiLuoTe百洛特),GSestimatedsalesof~Rmb100min'16,antidepressant,~4.6%marketsharein'16,competingwithLundbeck(originator)andJewinPharm(first-to-marketgeneric);-Kangfuxinoralsolution(brand:TianShuXin,天舒欣),TCMbasedpreparationforhealingulcerandinjuries,GSestimatedsalesof~Rmb150min'16












R&DR&Dteam:~1,200,targets1,500innearfutureKeymanagement:Dr.WangJingyi(王晶翼)-ChiefScientist,DirectorBio:JoinedKeluninNov.2012torebuildR&Dplatform.PriortoKelun,Mr.WangwastheR&DheadofQiluPharmafrom2002,leadingateamtolaunch30+keyproductsinChinawith20+noveldrugsatclinicaltrialstage.Dr.WangobtainedPhDdegreeonmedicalmolecularvirologyfromTheFourthMilitaryMedicalUniversitySales/marketingSalesteam:30+academicmarketing+over20,000agentsKeymanagement:Mr.ZhouXiaodong(周晓东)-ViceGeneralManagerBio:JoinedKeluninAug.2016tooverseemarketingandmedicaldepartment.PriortoKelun,Mr.Zhouheldvariousrolesinthemarketingdepartment,includingMarketingDirectorinHansohPharma(8years)andCTTQ(SinoBiopharm,8years).Beforethat,Mr.Zhouwasagastroenterologist(10years)


ALK/ROS1/BRAF/EGFR/VEGF/HER2/RET:DifferentgenesthataretargetsofcancertargetedtherapiestointerferetheproliferationofcancercellsANDA:Abbreviatednewdrugapplication,applicationusedwhenapplyingforapprovalofgenericdrugsintheUSARO:Academicresearchorganization,suchashospitalsanduniversitiesCephalosporin/Carbapenem:DifferenttypesofantibioticsforthetreatmentofinfectionsCordyceps:Agenusofascomycetefungi,referringtoDongchongxiacao(冬虫夏草)intheingredientofCorbrincapsule




本人，陈子易，在此申明，本报告所表述的所有观点准确反映了本人对上述公司或其证券的个人看法。此外，本人薪金的任何部分不曾与，不与，也将不会与本报告中的具体推荐意见或观点直接或间接相关。
Quantum是提供具体财务报表数据历史、预测和比率的高盛专有数据库，它可以用于对单一公司的深入分析，或在不同行业和市场的公司之间进行比较。
陈子易：A股医药。A股医药：贝达药业、ChengduKanghongPharmaceutical、HangzhouTigermedConsultingCo.、华东医药、华兰生物、恒瑞医药、恩华药业、丽珠集团、复星医药(A)
投资摘要部分通过将一只股票的主要指标与其行业和市场相比较来评价该股的投资环境。所描述的四个主要指标包括增长、回报、估值倍数和波动性。增长、回报和估值倍数都是运用数种方法综合计算而成，以确定该股在地区研究行业内所处的百分位排名。每项指标的准确计算方式可能随着财务年度、行业和所属地区的不同而有所变化，但标准方法如下：增长是下一年预测与当前年度预测的综合比较，如每股盈利、EBITDA和收入等。回报是各项资本回报指标一年预测的加总，如CROCI、平均运用资本回报率和净资产回报率。估值倍数根据一年预期估值比率综合计算，如市盈率、股息收益率、EV/FCF、EV/EBITDA、EV/DACF、市净率。波动性根据12个月的历史波动性计算并经股息调整。
在我们的全球覆盖范围中，我们使用并购框架来分析股票，综合考虑定性和定量因素（各行业和地区可能会有所不同）以计入某些公司被收购的可能性。然后我们按照从1到3对公司进行并购评分，其中1分代表公司成为并购标的的概率较高(30%-50%)，2分代表概率为中等(15%-30%)，3分代表概率较低(0%-15%)。对于评分为1或2的公司，我们按照研究部统一标准将并购因素体现在我们的目标价格当中。并购评分为3被认为意义不大，因此不予体现在我们的目标价格当中，分析师在研究报告中可以予以讨论或不予讨论。
GSSUSTAIN是一项侧重于通过发现优质行业领先企业而实现长期超额收益的全球投资策略。GSSUSTAIN50关注名单列出了我们认为凭借出色的资本回报、具有可持续性的竞争优势和对ESG（环境、社会和企业治理）风险的有效管理而有望在长期内相对于全球同业表现出色的行业领军企业。候选企业主要基于对企业在这三方面表现的综合量化分析筛选而出。


暂无评级(NR)：在高盛于涉及该公司的一项合并交易或战略性交易中担任咨询顾问时并在某些其他情况下，投资评级和目标价格已经根据高盛的政策予以除去。暂停评级(RS)：由于缺乏足够的基础去确定投资评级或价格目标，或在发表报告方面存在法律、监管或政策的限制，我们已经暂停对这种股票给予投资评级和价格目标。此前对这种股票作出的投资评级和价格目标(如有的话)将不再有效，因此投资者不应依赖该等资料。暂停研究(CS)：我们已经暂停对该公司的研究。没有研究(NC)：我们没有对该公司进行研究。不存在或不适用(NA)：此资料不存在或不适用。无意义(NM)：此资料无意义，因此不包括在报告内。
本报告在中国由高华证券分发。高华证券具备证券投资咨询业务资格。本研究报告仅供我们的客户使用。除了与高盛相关的披露，本研究报告是基于我们认为可靠的目前已公开的信息，但我们不保证该信息的准确性和完整性，客户也不应该依赖该信息是准确和完整的。报告中的信息、观点、估算和预测均截至报告的发表日，且可能在不事先通知的情况下进行调整。我们会适时地更新我们的研究，但各种规定可能会阻止我们这样做。除了一些定期出版的行业报告之外，绝大多数报告是在分析师认为适当的时候不定期地出版。高盛高华为高华证券的关联机构，从事投资银行业务。高华证券、高盛高华及它们的关联机构与本报告中涉及的大部分公司保持着投资银行业务和其它业务关系。我们的销售人员、交易员和其它专业人员可能会向我们的客户及自营交易部提供与本研究报告中的观点截然相反的口头或书面市场评论或交易策略。我们的资产管理部门、自营交易部和投资业务部可能会做出与本报告的建议或表达的意见不一致的投资决策。本报告中署名的分析师可能已经与包括高华证券销售人员和交易员在内的我们的客户讨论，或在本报告中讨论交易策略，其中提及可能会对本报告讨论的证券市场价格产生短期影响的推动因素或事件，该影响在方向上可能与分析师发布的股票目标价格相反。任何此类交易策略都区别于且不影响分析师对于该股的基本评级，此类评级反映了某只股票相对于报告中描述的研究范围内股票的回报潜力。高华证券及其关联机构、高级职员、董事和雇员，不包括股票分析师和信贷分析师，将不时地根据适用的法律和法规对本研究报告所涉及的证券或衍生工具持有多头或空头头寸，担任上述证券或衍生工具的交易对手，或买卖上述证券或衍生工具。在高盛组织的会议上的第三方演讲嘉宾（包括高华证券或高盛其它部门人员）的观点不一定反映全球投资研究部的观点，也并非高华证券或高盛的正式观点。在任何要约出售股票或征求购买股票要约的行为为非法的地区，本报告不构成该等出售要约或征求购买要约。本报告不构成个人投资建议，也没有考虑到个别客户特殊的投资目标、财务状况或需求。客户应考虑本
